Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225001 · ClinicalTrials.gov registry record · NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve
A NA study, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- NA
- Development phase
- 197
- Enrollment target
NCT03225001 is a NA study that has completed, run by Edwards Lifesciences. The registered enrollment target is 197 participants.
The verdict
NCT03225001, a NA study, has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 197 participants
- Enrollment target
Study Summary
To assess the safety and effectiveness of the SAPIEN XT transcatheter heart valve in patients with a failing surgical aortic bioprosthetic valve.
Interventions
- DEVICE Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2012-06-11 |
| Est. Completion | 2020-10-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03225001
The ClinicalTrials.gov registry entry for NCT03225001 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Edwards SAPIEN XT transcatheter valve, Model 9300TFX is the first listed.
NCT03225001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03225001 about?
NCT03225001 is a clinical study titled "PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve". To assess the safety and effectiveness of the SAPIEN XT transcatheter heart valve in patients with a failing surgical aortic bioprosthetic valve.
What is the current status of trial NCT03225001?
This trial is currently completed. It is a NA study. The enrollment target is 197 participants. The study started on 2012-06-11. Estimated completion is 2020-10-28.
What interventions are being tested in trial NCT03225001?
The interventions under investigation include: Edwards SAPIEN XT transcatheter valve, Model 9300TFX (DEVICE).
Who is sponsoring clinical trial NCT03225001?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.